Literature DB >> 20462366

Distribution of neprilysin and deposit patterns of Abeta subtypes in the brains of aged squirrel monkeys (Saimiri sciureus).

James K Chambers1, Hiroyuki Kuribayashi, Shu-Ichi Ikeda, Yumi Une.   

Abstract

Beta-amyloid (Abeta) is deposited in the parenchyma and blood vessel walls of the senescent brain, and forms lesions termed senile plaques (SPs) and cerebral amyloid angiopathy (CAA). Since in Alzheimer's disease (AD) excessive Abeta is linked to cognitive deterioration, the mechanisms of degradation and clearance of Abeta are now being researched for use in AD therapy. We conducted an immunohistochemical study of the patterns of deposition of two Abeta subtypes (Abeta40 and Abeta42) and the distribution of the Abeta degrading enzyme neprilysin (NEP) in the brains of aged squirrel monkeys, a species known to develop CAA and SPs. Abeta deposits were observed mainly in the cerebral cortex of five older monkeys, and were absent in monkeys under 12 years of age. NEP expression was observed in the caudate nucleus, putamen, globus pallidus, substantia nigra and the molecular layer of the dentate gyrus, and thus exhibited a distribution complementary to those of CAA and SPs in cerebral cortex and hippocampus. It is known that CAA is more prominent than SPs in squirrel monkey brains. However, we confirmed that Abeta40 is deposited predominantly in the arterioles of the meninges and penetrates vertically into the cerebral cortex, whereas Abeta42 is deposited predominantly in the capillaries of the cerebral cortex. These distinct patterns of deposition of Abeta subtypes are likely related to the difference in biochemical character of these two subtypes. We have demonstrated for the first time the distribution of NEP in the brain of a non-human primate, the squirrel monkey, which appears useful for research on AD treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20462366     DOI: 10.3109/13506129.2010.483119

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


  7 in total

Review 1.  Nonhuman primate models of Alzheimer-like cerebral proteopathy.

Authors:  Eric Heuer; Rebecca F Rosen; Amarallys Cintron; Lary C Walker
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

2.  Acute ethanol administration differentially alters enkephalinase and aminopeptidase N activity and mRNA levels in regions of the nigrostriatal pathway.

Authors:  Marcela Morales-Mulia; Patricia de Gortari; María-Isabel Amaya; Milagros Méndez
Journal:  J Mol Neurosci       Date:  2012-06-12       Impact factor: 3.444

Review 3.  Contributions of Nonhuman Primates to Research on Aging.

Authors:  E S Didier; A G MacLean; M Mohan; P J Didier; A A Lackner; M J Kuroda
Journal:  Vet Pathol       Date:  2016-02-11       Impact factor: 2.221

Review 4.  Alzheimer's disease: experimental models and reality.

Authors:  Eleanor Drummond; Thomas Wisniewski
Journal:  Acta Neuropathol       Date:  2016-12-26       Impact factor: 17.088

5.  Neurofibrillary tangles and the deposition of a beta amyloid peptide with a novel N-terminal epitope in the brains of wild Tsushima leopard cats.

Authors:  James K Chambers; Kazuyuki Uchida; Tomoyuki Harada; Masaya Tsuboi; Masumi Sato; Masahito Kubo; Hiroaki Kawaguchi; Noriaki Miyoshi; Hajime Tsujimoto; Hiroyuki Nakayama
Journal:  PLoS One       Date:  2012-10-03       Impact factor: 3.240

Review 6.  Research Relevant Conditions and Pathology in Nonhuman Primates.

Authors:  Chandra Saravanan; Thierry Flandre; Carolyn L Hodo; Anne D Lewis; Lars Mecklenburg; Annette Romeike; Oliver C Turner; Hsi-Yu Yen
Journal:  ILAR J       Date:  2020-12-31       Impact factor: 1.521

7.  Development of an optogenetic toolkit for neural circuit dissection in squirrel monkeys.

Authors:  Daniel J O'Shea; Paul Kalanithi; Emily A Ferenczi; Brian Hsueh; Chandramouli Chandrasekaran; Werapong Goo; Ilka Diester; Charu Ramakrishnan; Matthew T Kaufman; Stephen I Ryu; Kristen W Yeom; Karl Deisseroth; Krishna V Shenoy
Journal:  Sci Rep       Date:  2018-04-30       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.